中邮证券：siRNA药物机制优势突出 递送为核心技术

Group 1 - The core advantage of siRNA drugs lies in their ability to precisely silence pathogenic proteins, with delivery systems being the key technology [1] - siRNA therapies are gaining popularity in new drug development due to their high efficiency in degrading proteins and prolonged action time compared to traditional small molecules and biologics [1] - The focus of technological breakthroughs is on extrahepatic delivery, with various delivery methods such as LNP, antibodies, peptides, and VLP, each having its own advantages and disadvantages [1] Group 2 - Overseas giants like Alnylam have entered a harvest phase with their GalNAc liver delivery platform, which is recognized for its high efficiency and specificity [2] - Other companies such as Arrowhead and Dicerna are advancing siRNA drugs targeting common cardiovascular markers and are in late-stage clinical or commercial phases [2] - Research on extrahepatic delivery for muscle, nervous system, and ocular targets is still in early development, with potential seen in Alnylam's C16 platform and Arrowhead's TRiM platform [2] Group 3 - Domestic siRNA drug development is flourishing, with a variety of directions from startups and major pharmaceutical companies entering the field [3] - Collaborations between domestic companies and multinational corporations (MNCs) are increasing, with notable partnerships established with Novartis, Roche, and GSK [3] - Domestic firms are actively pursuing dual-target and extrahepatic delivery strategies, narrowing the gap with overseas competitors and potentially leading industry development [3]